Cytek Biosciences (CTKB) Competitors $5.11 +0.17 (+3.44%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends CTKB vs. ALLO, VALN, PRTA, TRNS, LAB, EYPT, AEHR, QTRX, NAUT, and SENSShould you be buying Cytek Biosciences stock or one of its competitors? The main competitors of Cytek Biosciences include Allogene Therapeutics (ALLO), Valneva (VALN), Prothena (PRTA), Transcat (TRNS), Standard BioTools (LAB), EyePoint Pharmaceuticals (EYPT), Aehr Test Systems (AEHR), Quanterix (QTRX), Nautilus Biotechnology (NAUT), and Senseonics (SENS). Cytek Biosciences vs. Allogene Therapeutics Valneva Prothena Transcat Standard BioTools EyePoint Pharmaceuticals Aehr Test Systems Quanterix Nautilus Biotechnology Senseonics Allogene Therapeutics (NASDAQ:ALLO) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, community ranking, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations. Which has more risk & volatility, ALLO or CTKB? Allogene Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, Cytek Biosciences has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500. Does the MarketBeat Community favor ALLO or CTKB? Allogene Therapeutics received 258 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 65.33% of users gave Allogene Therapeutics an outperform vote while only 44.19% of users gave Cytek Biosciences an outperform vote. CompanyUnderperformOutperformAllogene TherapeuticsOutperform Votes27765.33% Underperform Votes14734.67% Cytek BiosciencesOutperform Votes1944.19% Underperform Votes2455.81% Is ALLO or CTKB more profitable? Cytek Biosciences has a net margin of -8.88% compared to Allogene Therapeutics' net margin of -223,139.98%. Cytek Biosciences' return on equity of -3.75% beat Allogene Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Allogene Therapeutics-223,139.98% -50.24% -40.21% Cytek Biosciences -8.88%-3.75%-3.00% Does the media favor ALLO or CTKB? In the previous week, Allogene Therapeutics had 7 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for Allogene Therapeutics and 1 mentions for Cytek Biosciences. Allogene Therapeutics' average media sentiment score of 0.24 beat Cytek Biosciences' score of 0.00 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate ALLO or CTKB? Allogene Therapeutics currently has a consensus price target of $9.96, suggesting a potential upside of 266.01%. Cytek Biosciences has a consensus price target of $8.50, suggesting a potential upside of 66.34%. Given Allogene Therapeutics' higher possible upside, analysts clearly believe Allogene Therapeutics is more favorable than Cytek Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Allogene Therapeutics 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.73Cytek Biosciences 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Do insiders and institutionals believe in ALLO or CTKB? 83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 24.3% of Allogene Therapeutics shares are held by insiders. Comparatively, 9.6% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Which has stronger valuation & earnings, ALLO or CTKB? Cytek Biosciences has higher revenue and earnings than Allogene Therapeutics. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAllogene Therapeutics$90K6,319.77-$327.27M-$1.61-1.69Cytek Biosciences$193.01M3.48-$12.15M-$0.14-36.50 SummaryAllogene Therapeutics beats Cytek Biosciences on 10 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. Get Cytek Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CTKB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTKB vs. The Competition Export to ExcelMetricCytek BiosciencesAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$672.02M$5.76B$5.33B$8.52BDividend YieldN/A0.43%5.07%4.13%P/E Ratio-36.5029.42128.5116.13Price / Sales3.483.961,489.1693.42Price / Cash194.2637.9639.6734.18Price / Book1.762.624.765.07Net Income-$12.15M$515,312.50$119.00M$225.46M7 Day Performance8.96%4.04%0.79%0.54%1 Month Performance-2.48%-2.53%5.64%3.75%1 Year Performance19.11%-9.84%36.71%29.48% Cytek Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTKBCytek Biosciences1.8412 of 5 stars$5.11+3.4%$8.50+66.3%+21.1%$672.02M$193.01M-36.50500Upcoming EarningsPositive NewsALLOAllogene Therapeutics3.0217 of 5 stars$2.44-3.9%$9.96+308.0%-3.9%$509.96M$65,000.00-1.52232Upcoming EarningsAnalyst ForecastNews CoverageVALNValneva1.54 of 5 stars$5.94+0.8%$18.50+211.4%-50.6%$413.65M$150.78M-11.42700High Trading VolumePRTAProthena3.2104 of 5 stars$15.30-6.0%$61.86+304.3%-54.6%$822.71M$217.25M-15.30173Upcoming EarningsTRNSTranscat3.8728 of 5 stars$119.76-3.0%$151.33+26.4%+7.0%$1.09B$265.59M70.861,104Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLABStandard BioTools2.6592 of 5 stars$1.68-2.9%$3.00+78.6%+1.5%$622.31M$136.30M-1.85620Earnings ReportAnalyst ForecastNews CoverageEYPTEyePoint Pharmaceuticals2.8111 of 5 stars$9.50-0.6%$29.00+205.3%+66.6%$494.80M$50.39M-5.31120Upcoming EarningsAnalyst ForecastAEHRAehr Test Systems2.9251 of 5 stars$16.96+8.9%$25.00+47.4%-49.2%$490.40M$58.71M15.1490Gap DownQTRXQuanterix2.5424 of 5 stars$12.47+2.1%$23.00+84.4%-37.4%$477.23M$127.95M-11.88460Upcoming EarningsNAUTNautilus Biotechnology1.939 of 5 stars$2.69-1.1%$4.50+67.3%+2.0%$336.96MN/A-4.80130Earnings ReportNews CoverageSENSSenseonics2.1182 of 5 stars$0.34-3.0%$2.00+491.7%N/A$179.44M$24.04M-2.6090Analyst Forecast Related Companies and Tools Related Companies Allogene Therapeutics Alternatives Valneva Alternatives Prothena Alternatives Transcat Alternatives Standard BioTools Alternatives EyePoint Pharmaceuticals Alternatives Aehr Test Systems Alternatives Quanterix Alternatives Nautilus Biotechnology Alternatives Senseonics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTKB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytek Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytek Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
